Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET

THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET.

Benzinga’s Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health. Join the event for a dynamic exploration of the healthcare and biotech landscape, covering topics including AI, telemedicine, oncology, medical devices, healthcare M&A activity, and the latest start-ups.

To register for the event and access the Autonomix presentation, please visit the Benzinga Virtual Healthcare Summit 2024 event website.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com

Staff

Recent Posts

The Surface Treatment Of Medical Components With Mass Finishing & Shot Blasting

By Colin Spellacy, Head of Sales, Rösler UK In the demanding field of medical device…

42 mins ago

Syllable Corporation Announces Purchase of Actium Health

Syllable expands artificial intelligence offerings to health systems through the purchase of Actium Health’s patient…

2 hours ago

CBIH Commences Clinical Trials of Osteoarthritis Injection “Orthocann”

Houston, Texas--(Newsfile Corp. - March 20, 2024) - Cannabis Bioscience International Holdings, Inc. (OTC Pink:…

2 hours ago

Voluntary Removal Announcement for the InfuTronix Nimbus Ambulatory Infusion Pump System

NATICK, MA / ACCESSWIRE / March 20, 2024 / InfuTronix, LLC has announced a voluntary…

2 hours ago

Fusion Wins 2024 Best Place to Work in Omaha Award, Earns Sixth Placement on the List

Omaha-based healthcare company Fusion is named Baird Holm's 2024 Best Place to Work in the…

2 hours ago